Download PDF
Zeitschrift für Orthomolekulare Medizin 2023; 21(01): 16-24
DOI: 10.1055/a-2014-4012
Wissen

Autoimmunerkrankungen und Vitamin D

Uwe Gröber
,
Michael F. Holick
› Further Information
    Permissions and Reprints

Zusammenfassung

Die biologisch aktive Form von Vitamin D, das Secosteroidhormon 1,25(OH)2D, moduliert zahlreiche Gene des angeborenen und adaptiven Immunsystems über Regulation seines Transkriptionsfaktors Vitamin-D-Rezeptor (VDR). Der Beitrag stellt den Einfluss des Prohormons auf das Epigenom vor und den aktuellen Stellenwert in der Therapie von Autoimmunerkrankungen, z. B. Multiple Sklerose, sowie bei einer Vitamin-D-Resistenz.

Schlüsselwörter

Autoimmunerkrankungen - Vitamin D - Vitamin-D-Rezeptor - Multiple Sklerose - Parathormon - Epigenom - DNA-Methylierung - Vitamin-D-Resistenz - Coimbra-Protokoll


Publication History

Article published online:
24 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Carlberg C.. Nutrigenomics of Vitamin D. Nutrients 2019; 11: 676
    CrossrefPubMedGoogle Scholar
  • 2 Seuter S, Neme A, Carlberg C.. Epigenome-wide effects of vitamin D and their impact on the transcriptome of human monocytes involve CTCF. Nucleic Acids Res 2016; 44: 4090-4104
    CrossrefPubMedGoogle Scholar
  • 3 Bikle DD.. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chem Biol 2014; 21: 319-329
    CrossrefPubMedGoogle Scholar
  • 4 Arnson Y, Amital H. , Shoenfeld. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137-1142
    CrossrefPubMedGoogle Scholar
  • 5 Murdaca G, Tonacci A, Negrini S. et al. Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications. Autoimmun Rev 2019; 18: 102350
    CrossrefPubMedGoogle Scholar
  • 6 Gröber U, Holick MF.. Vitamin D: Die Heilkraft des Sonnenvitamins. 4., aktual. und erw. Aufl.. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2020
    Google Scholar
  • 7 Gröber U, Spitz J, Reichrath J. et al. Vitamin D: Update 2013. From rickets prophylaxis to general preventive healthcare. Dermatoendocrinol 2013; 5: 331-347
    CrossrefPubMedGoogle Scholar
  • 8 Matsuoka LY, Wortsman, Haddad JG. et al. In vivo threshold for cutaneous synthesis of vitamin D3. J Lab Clin Med 1989; 114: 301-305
    PubMedGoogle Scholar
  • 9 Jones G, Prosser DE, Kaufmann M.. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 2014; 55: 13-31
    CrossrefPubMedGoogle Scholar
  • 10 Cashman KD, van den Heuvel EG, Schoemaker RJ. et al. 25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population. Adv Nutr 2017; 8: 947-957
    CrossrefPubMedGoogle Scholar
  • 11 Fatima M, Lamis A, Siddiqui S. et al. Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept. Cureus 2022; 14: e26186
    PubMedGoogle Scholar
  • 12 Finamor DC, Siningaglia-Coimbra R, Neves LCM. et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Dermatoendocrinol 2013; 5: 222-234
    CrossrefPubMedGoogle Scholar
  • 13 Saksa N, Neme A, Ryynänen J. et al. Dissecting high from low responders in a vitamin D3 intervention study. J Steroid Biochem Mol Biol 2015; 148: 275-282
    CrossrefPubMedGoogle Scholar
  • 14 Seuter S, Virtanen JK, Nurmi T. et al. Molecular evaluation of vitamin D responsiveness of healthy young adults. J Steroid Biochem Mol Biol 2017; 174: 314-321
    PubMedGoogle Scholar
  • 15 Carlberg C, Haq A.. The concept of the personal vitamin D response index. J Steroid Biochem Mol Biol 2018; 175: 12-17
    CrossrefPubMedGoogle Scholar
  • 16 Lu M, McComish BJ, Burdon KP. et al. The Association Between Vitamin D and Multiple Sclerosis Risk: 1,25(OH)2D3 Induces Super-Enhancers Bound by VDR. Front Immunol 2019; 10: 488
    CrossrefPubMedGoogle Scholar
  • 17 Huertas J, Schöler HR, Cojocaru V.. Histone tails cooperate to control the breathing of genomic nucleosomes. PLoS Comp Biol 2021; 17: e1009013
    CrossrefPubMedGoogle Scholar
  • 18 Fetahu IS, Höbaus J, Kallay E.. Vitamin D and the epigenome. Front Physiol 2014; 5: 164
    CrossrefPubMedGoogle Scholar
  • 19 Papin C, Le Gras S, Ibrahim A. et al. CpG Islands Shape the Epigenome Landscape. J Mol Biol 2021; 433: 166659
    CrossrefPubMedGoogle Scholar
  • 20 Carlberg C, Seuter S, Numi T. et al. In vivo response of the human epigenome to vitamin D: A Proof-of-principle study. J Steroid Biochem Mol Biol 2018; 180: 142-148
    CrossrefPubMedGoogle Scholar
  • 21 Hossein-nezhad A, Spira A, Holick MF. Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One 2013; 8: e58725
    CrossrefPubMedGoogle Scholar
  • 22 Kurtzke JF.. Geography in multiple sclerosis. J Neurol 1977; 215: 1-26
    CrossrefPubMedGoogle Scholar
  • 23 Ascherio A, Munger KL.. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61: 288-299
    CrossrefPubMedGoogle Scholar
  • 24 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61: 504-513
    CrossrefPubMedGoogle Scholar
  • 25 Antico A, Tampoia M, Tozzoli R. et al. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012; 12: 127-136
    CrossrefPubMedGoogle Scholar
  • 26 Eftekharian MM, Noroozi R, Sayad A. et al. RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis. J Neurol Sci 2016; 369: 259-262
    CrossrefPubMedGoogle Scholar
  • 27 Slominski AT, Kim TK, Takeda Y. et al. RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J 2014; 28: 2775-2789
    CrossrefPubMedGoogle Scholar
  • 28 Slominski AT, Kim TK, Hobrath JV. et al. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ. J Steroid Biochem Mol Biol 2017; 173: 42-56
    CrossrefPubMedGoogle Scholar
  • 29 Ascherio A, Munger KL, White R. et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71: 306-314
    CrossrefPubMedGoogle Scholar
  • 30 Hahn J, Cook NR, Alexander EK. et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ 2022; 376: e066452
    CrossrefPubMedGoogle Scholar
  • 31 Sirbe C, Rednic S, Grama A. et al. An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases. Int J Mol Sci 2022; 23: 9784
    CrossrefPubMedGoogle Scholar
  • 32 Shinto L, Marracci G, Baldauf-Wagner S. et al. Omega-3-fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids 2009; 80: 131-136
    CrossrefPubMedGoogle Scholar
  • 33 Ramirez-Ramirez V, Macias-Isalas MA, Ortiz GG. et al. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. Oxid Med Cell Longev 2013; 2013: 709493 DOI: 10.1155/2013/709493.
    CrossrefPubMedGoogle Scholar
  • 34 Yu H, Bai S, Hao Y. et al. Fatty acids role in multiple sclerosis as “metabokines”.. J Neuroinflammation 2022; 19: 157
    CrossrefPubMedGoogle Scholar
  • 35 Jagannath VA, Filippini G, Pietrantonj CD. et al. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev 2018; 9: CD008422
    PubMedGoogle Scholar
  • 36 Hupperts R, Smolders J, Vieth R. et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology 2019; 93: e1906-e1916
    CrossrefPubMedGoogle Scholar
  • 37 Camu W, Lehert P, Pierrot-Deseilligny C. et al. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm 2019; 6: e597
    CrossrefPubMedGoogle Scholar
  • 38 Smolders J, Torkildsen O, Camu W. et al. An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs 2019; 33: 1187-1199
    CrossrefPubMedGoogle Scholar
  • 39 Fitzgerald KC, Munger KL, Köchert K. et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 2015; 72: 1458-1465
    CrossrefPubMedGoogle Scholar
  • 40 Lemke D, Klement RJ, Schweiger F. et al. Vitamin D Resistance as a Possible Cause of Autoimmune Diseases: A Hypothesis Confirmed by a Therapeutic High-Dose Vitamin D Protocol. Front Immunol 2021; 12: 655739
    CrossrefPubMedGoogle Scholar
  • 41 Hanel A, Carlberg C.. Time-Resolved Gene Expression Analysis Monitors the Regulation of Inflammatory Mediators and Attenuation of Adaptive Immune Response by Vitamin D. Int J Mol Sci 2022; 23: 911
    CrossrefPubMedGoogle Scholar
  • 42 Seuter S, Virtanen JK, Nurmi T. et al. Molecular evaluation of vitamin D responsiveness of healthy young adults. J Steroid Biochem Mol Biol 2017; 174: 314-321
    CrossrefPubMedGoogle Scholar
  • 43 Holick MF, Binkley NC, Bischoff-Ferrari HA. et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930
    CrossrefPubMedGoogle Scholar
  • 44 Holick MF.. Vitamin D is not as toxic as was once thought: a historical and up-to-date perspective. Mayo Clin Proc 2015; 90: 561-564
    CrossrefPubMedGoogle Scholar
  • 45 Sotirchos ES, Bhargava P, Eckstein C. et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology 2016; 86: 382-390
    CrossrefPubMedGoogle Scholar
  • 46 Marcinowska-Suchowierska E, Kupisz-Urbanska M, Lukaszkiewicz J. et al. Vitamin D Toxicity–A Clinical Perspective. Front Endocrinol (Lausanne) 2018; 9: 550
    CrossrefPubMedGoogle Scholar
  • 47 Amon U, Yaguboglu R, Ennis M, Holick MF, Amon J.. Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”. Nutrients 2022; 14: 1575
    CrossrefPubMedGoogle Scholar
  • 48 Koivisto O, Hanel A, Carlberg C.. Key Vitamin D Target Genes with Functions in the Immune System. Nutrients 2020; 12: 1140
    CrossrefPubMedGoogle Scholar